Trial · NCT06212492
Effects on Biotrauma of NMBAs and PP Association During ARDS
NCT06212492, Not applicable, Recruiting, Assistance Publique Hopitaux De Marseille
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects on Biotrauma of NMBAs and PP Association During ARDS. Trials, record NCT06212492. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06212492
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects on Biotrauma of NMBAs and PP Association During ARDS
- NCT number
- NCT06212492
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Assistance Publique Hopitaux De Marseille
- Conditions
- Moderate to Severe Acute Respiratory Distress Syndrome
- Interventions
- NMBAs, Prone positioning
- First posted
- 2024-01-19
- Last updated
- 2024-08-20
Source ClinicalTrials.gov
Registered outcomes102
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Difference between the plasma sRAGE value at the end of the first PP session and the baseline value before PP (∆ sRAGE). | Day 1 | Our primary outcome will be the comparison of the differences in plasma sRAGE levels before and after the first PP session (∆ sRAGE), a kinetic being probably more relevant than a raw value, given the observed inter-individual variations of sRAGE at basal state. |
| Secondary | Plasma determination of IL1 before the first PP session | Day 1 | Inflammation, pulmonary epithelial and endothelial dysfunction |
| Secondary | Plasma determination of IL1 1 hour after PP initiation at the first PP session | Day 1 | Inflammation, pulmonary epithelial and endothelial dysfunction |
| Secondary | Plasma determination of IL1 at the end of the first PP session | Day 1 | Inflammation, pulmonary epithelial and endothelial dysfunction |
| Secondary | Plasma determination of IL1 4 hours after return to supine after the first PP session | Day 2 | Inflammation, pulmonary epithelial and endothelial dysfunction |
| Secondary | Plasma determination of TNFα before the first PP session | Day 1 | Inflammation, pulmonary epithelial and endothelial dysfunction |
| Secondary | Plasma determination of TNFα 1 hour after PP initiation at the first PP session | Day 1 | Inflammation, pulmonary epithelial and endothelial dysfunction |
| Secondary | Plasma determination of TNFα at the end of the first PP session | Day 1 | Inflammation, pulmonary epithelial and endothelial dysfunction |
| Secondary | Plasma determination of TNFα 4 hours after return to supine after the first PP session | Day 2 | Inflammation, pulmonary epithelial and endothelial dysfunction |
| Secondary | Plasma determination of sRAGE before the first PP session | Day 1 | Inflammation, pulmonary epithelial and endothelial dysfunction |
1 to 10 of 102Source ClinicalTrials.gov
See all 102 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06212492
GET https://conductscience.org/api/trials/v1/NCT06212492/registered?page=2